Fasenra and Ocular hyperaemia - a phase IV clinical study of FDA data

Summary:

Ocular hyperaemia is reported as a side effect among people who take Fasenra (benralizumab), especially for people who are female, 60+ old, have been taking the drug for < 1 month also take Dupixent, and have Asthma.

The phase IV clinical study analyzes which people have Ocular hyperaemia when taking Fasenra. It is created by eHealthMe based on reports of 11,790 people who have side effects when taking Fasenra from the FDA, and is updated regularly.

What is Fasenra?

Fasenra has active ingredients of benralizumab. eHealthMe is studying from 11,805 Fasenra users. Check the latest studies of Fasenra.

What is Ocular hyperaemia?

Ocular hyperaemia (an abnormally large amount of blood in eye) is found to be associated with 1,357 drugs and 1,499 conditions by eHealthMe. Check the latest studies of Ocular hyperaemia.

On Jul, 14, 2026

11,790 people reported to have side effects when taking Fasenra.
Among them, 18 people (0.15%) have Ocular hyperaemia.

Among these 18 people:

How long have people been on Fasenra when they have Ocular hyperaemia? *

What is the gender of people who have Ocular hyperaemia when taking Fasenra? *

female: 70.59 %
male: 29.41 %

What is the age of people who have Ocular hyperaemia when taking Fasenra? *

What are other drugs people take besides Fasenra? *

What are other side effects people have besides Ocular hyperaemia? *

Asthma: 5 people, 27.78%
Eye Pruritus (eye itching): 4 people, 22.22%
Chest Pain: 3 people, 16.67%
Dyspnea (difficult or laboured breathing): 3 people, 16.67%
Hypersensitivity: 3 people, 16.67%
Nausea (feeling of having an urge to vomit): 2 people, 11.11%
Hoarseness Or Changing Voice: 2 people, 11.11%
Cough: 2 people, 11.11%
Nasal Congestion (blockage of the nasal passages usually due to membranes lining the nose becoming swollen from inflamed blood vessels): 2 people, 11.11%
Dry Eyes (lack of adequate tears): 2 people, 11.11%

What are the existing conditions these people have? *

Asthma: 14 people, 77.78%
Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 3 people, 16.67%
Periarthritis (inflammation of the external coats of an artery and of the tissues around the artery): 2 people, 11.11%
Nasal Polyps (masses that develop in the lining of the nose): 2 people, 11.11%
Muscle Spasms (muscle contraction): 2 people, 11.11%
Gastroenteritis (inflammation of stomach and intestine): 2 people, 11.11%
Dysmenorrhea (painful menstruation): 2 people, 11.11%
Conjunctivitis Allergic (inflammation of the conjunctiva due to allergy): 2 people, 11.11%
Itching: 1 person, 5.56%
Insomnia (sleeplessness): 1 person, 5.56%

* Approximation only. Some reports may have incomplete information.

Do you take Fasenra and have Ocular hyperaemia?

- Check whether Ocular hyperaemia is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Fasenra:

Fasenra (11,805 reports)

Browse all side effects of Fasenra:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Ocular hyperaemia:

Ocular hyperaemia (1,357 drugs)

Browse all the conditions that are associated with Ocular hyperaemia:

Ocular hyperaemia (1,499 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on benralizumab (the active ingredients of Fasenra) and Fasenra (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.